

<!DOCTYPE html>
<html>
<head>
    <title>全文阅读--XML全文阅读--中国知网</title>
    <link rel="icon" href="/kxreader/favicon.ico" />
    <link rel="shortcut Icon" href="/kxreader/favicon.ico" />
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
    <meta name="keywords" content="文献 XML KBASE CNKI 中国知网" />
    <meta name="description" content="XML文献检索" />
    <script type="text/javascript">
        var APPPATH = '/kxreader';
    </script>

</head>

<body>

    
<script type="text/javascript" src="//login.cnki.net/TopLogin/api/loginapi/get?type=top&amp;localCSS=&amp;returnurl=%2f%2fkns.cnki.net%2fKXReader%2fDetail%3fTIMESTAMP%3d637141640918881250%26DBCODE%3dCJFD%26TABLEName%3dCJFDLAST2019%26FileName%3dXXGK201905022%26RESULT%3d1%26SIGN%3dsi4D7jxrcn2ZyD1IDCa0IW%252fyW00%253d"></script>

<div id="headerBox" class="header">
    <div class="topbar">
        <div class="textalign">
            <a href="/kxreader/Detail?dbcode=CJFD&amp;filename=XXGK201905022&amp;align=md">
                <i class="icon-cen active" title="居中对齐"></i>
            </a>
            <a href="/kxreader/Detail?dbcode=CJFD&amp;filename=XXGK201905022&amp;align=lt">
                <i class="icon-left " title="左对齐"></i>
            </a>
        </div>
        <h6 class="free-tip"><i class="icon"></i>HTML阅读开放试用阶段，欢迎体验！</h6>
    </div>
</div>


    



<div class="btn-link" style="display: none"><a target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=XXGK201905022&amp;v=MzA0NDVSNFQ2ajU0TzN6cXFCdEdGckNVUjdxZlp1Wm1GeW5oVnJyQlBUWE1aYkc0SDlqTXFvOUhab1FLREg4NHY=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">知网节</a></div>

    <div class="main">

        

    <div class="sidebar-a">
        <!--sidebar start-->
        <div class="sidenav">
            <div class="arrow"><span></span></div>
            <!--sidebar_list start-->
            <dl class="sidenav-list">
                    <dt class="tit">目录结构</dt>
                            <dd class="guide">
                                    <p><a href="#51" data-title="&lt;b&gt;1 资料与方法&lt;/b&gt; "><b>1 资料与方法</b></a><i></i></p>
                                                                    <ul class="contentbox">
                                                <li><a href="#52" data-title="1.1 一般资料">1.1 一般资料</a></li>
                                                <li><a href="#55" data-title="1.2 方法">1.2 方法</a></li>
                                                <li><a href="#57" data-title="1.3 观察指标">1.3 观察指标</a></li>
                                                <li><a href="#59" data-title="1.4 统计学分析">1.4 统计学分析</a></li>
                                    </ul>
                            </dd>
                            <dd class="guide">
                                    <p><a href="#61" data-title="&lt;b&gt;2 结 果&lt;/b&gt; "><b>2 结 果</b></a><i></i></p>
                                                                    <ul class="contentbox">
                                                <li><a href="#62" data-title="2.1 两组血小板抑制率及血清MMP-2、hsCRP水平比较">2.1 两组血小板抑制率及血清MMP-2、hsCRP水平比较</a></li>
                                                <li><a href="#65" data-title="2.2 两组HRV指标比较">2.2 两组HRV指标比较</a></li>
                                                <li><a href="#68" data-title="2.3 两组MACE发生情况比较">2.3 两组MACE发生情况比较</a></li>
                                                <li><a href="#71" data-title="2.4 两组出血情况比较">2.4 两组出血情况比较</a></li>
                                    </ul>
                            </dd>
                            <dd class="guide">
                                    <p><a href="#74" data-title="&lt;b&gt;3 讨 论&lt;/b&gt; "><b>3 讨 论</b></a><i></i></p>
                                                            </dd>
                            <dd class="guide">
                                    <p><a href="#" data-title="文内图表 ">文内图表</a><i></i></p>
                                                                    <ul class="contentbox">
                                                <li><a href="#54" data-title="&lt;b&gt;表&lt;/b&gt;1 &lt;b&gt;两组&lt;/b&gt;CPGR-ACS&lt;b&gt;患者基线资料比较&lt;/b&gt;(n=69)"><b>表</b>1 <b>两组</b>CPGR-ACS<b>患者基线资料比较</b>(n=69)</a></li>
                                                <li><a href="#64" data-title="&lt;b&gt;表&lt;/b&gt;2 &lt;b&gt;两组血小板抑制率及血清&lt;/b&gt;MMP-2、hsCRP&lt;b&gt;水平比较&lt;/b&gt;&lt;mathml id=&quot;80&quot;&gt;&lt;math xmlns=&quot;http://www.w3.org/1998/Math/MathML&quot;&gt;&lt;mrow&gt;&lt;mo stretchy=&quot;false&quot;&gt;(&lt;/mo&gt;&lt;mover accent=&quot;true&quot;&gt;&lt;mi&gt;x&lt;/mi&gt;&lt;mo&gt;&#175;&lt;/mo&gt;&lt;/mover&gt;&lt;mo&gt;&#177;&lt;/mo&gt;&lt;mi&gt;s&lt;/mi&gt;&lt;mo&gt;,&lt;/mo&gt;&lt;mtext&gt;n&lt;/mtext&gt;&lt;mo&gt;=&lt;/mo&gt;&lt;mn&gt;6&lt;/mn&gt;&lt;mn&gt;9&lt;/mn&gt;&lt;mo stretchy=&quot;false&quot;&gt;)&lt;/mo&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/mathml&gt;"><b>表</b>2 <b>两组血小板抑制率及血清</b>MMP-2、hsCRP<b>水平比较</b><mathml id="80"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mo stretchy="false">(</mo><mover accent="true"><mi>x</mi><mo>¯</mo></mover><mo>±</mo><mi>s</mi><mo>,</mo><mtext>n</mtext><mo>=</mo><mn>6</mn><mn>9</mn><mo stretchy="false">)</mo></mrow></math></mathml></a></li>
                                                <li><a href="#67" data-title="&lt;b&gt;表&lt;/b&gt;3 &lt;b&gt;两组心率变异&lt;/b&gt;(HRV)&lt;b&gt;指标比较&lt;/b&gt;&lt;mathml id=&quot;81&quot;&gt;&lt;math xmlns=&quot;http://www.w3.org/1998/Math/MathML&quot;&gt;&lt;mrow&gt;&lt;mo stretchy=&quot;false&quot;&gt;(&lt;/mo&gt;&lt;mover accent=&quot;true&quot;&gt;&lt;mi&gt;x&lt;/mi&gt;&lt;mo&gt;&#175;&lt;/mo&gt;&lt;/mover&gt;&lt;mo&gt;&#177;&lt;/mo&gt;&lt;mi&gt;s&lt;/mi&gt;&lt;mo&gt;,&lt;/mo&gt;&lt;mtext&gt;n&lt;/mtext&gt;&lt;mo&gt;=&lt;/mo&gt;&lt;mn&gt;6&lt;/mn&gt;&lt;mn&gt;9&lt;/mn&gt;&lt;mo stretchy=&quot;false&quot;&gt;)&lt;/mo&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/mathml&gt;"><b>表</b>3 <b>两组心率变异</b>(HRV)<b>指标比较</b><mathml id="81"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mo stretchy="false">(</mo><mover accent="true"><mi>x</mi><mo>¯</mo></mover><mo>±</mo><mi>s</mi><mo>,</mo><mtext>n</mtext><mo>=</mo><mn>6</mn><mn>9</mn><mo stretchy="false">)</mo></mrow></math></mathml></a></li>
                                                <li><a href="#70" data-title="&lt;b&gt;表&lt;/b&gt;4 &lt;b&gt;两组&lt;/b&gt;MACE&lt;b&gt;发生情况比较&lt;/b&gt;(n=69)"><b>表</b>4 <b>两组</b>MACE<b>发生情况比较</b>(n=69)</a></li>
                                                <li><a href="#73" data-title="&lt;b&gt;表&lt;/b&gt;5 &lt;b&gt;两组出血情况比较&lt;/b&gt;(n=69)"><b>表</b>5 <b>两组出血情况比较</b>(n=69)</a></li>
                                    </ul>
                            </dd>
                                    <dd class="guide">
                                        <h6>
                                            <p><a href="#a_bibliography">参考文献</a> </p>
                                        </h6>
                                    </dd>

            </dl>
        </div>
        <!--sidebar end-->
        &nbsp;
        <!--此处有一空格符 勿删-->
    </div>

                <div class="sidebar-b three-collumn" style="width:0;">
            <div class="refer" style="width: 0;">
                <div class="arrow off" title="参考文献"><span></span></div>
                <div class="js-scrollbox" >
                    
                    <div class="subbox active">
                        <h4>
                            <span class="tit">参考文献</span>
                            <a class="close" href="javascript:void(0)">x</a>
                        </h4>
                        <div class="side-scroller">
                            <ul class="refer-list">
                                <li id="5">


                                    <a id="bibliography_1" title="Zakroysky P,Thai WE,Deaňo RC,et al.Steroid exposure,acute coronary syndrome,and inflammatory bowel disease:insights into the inflammatory milieu[J].Am J Med,2015,128(3):303-311." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES14121200000970&amp;v=MTM4ODJQTnJZOUZaT3NQQlhzNW9CTVQ2VDRQUUgvaXJSZEdlcnFRVE1ud1plWnRGaW5sVXJmSUlWb1JieHM9TmlmT2ZiSzhIOQ==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[1]</b>
                                        Zakroysky P,Thai WE,Deaňo RC,et al.Steroid exposure,acute coronary syndrome,and inflammatory bowel disease:insights into the inflammatory milieu[J].Am J Med,2015,128(3):303-311.
                                    </a>
                                </li>
                                <li id="7">


                                    <a id="bibliography_2" title="Alcock RF,Yong AS,Ng AC,et al.Acute coronary syndrome and stable coronary artery disease:are they so different?Long-term outcomes in a contemporary PCI cohort[J].Int J Cardiol,2013,167(4):1343-1346." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13012300499533&amp;v=MjU3NDlNbndaZVp0RmlubFVyZklJVm9SYnhzPU5pZk9mYks3SHRET3JJOUZZT0lHQ1g4Nm9CTVQ2VDRQUUgvaXJSZEdlcnFRVA==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[2]</b>
                                        Alcock RF,Yong AS,Ng AC,et al.Acute coronary syndrome and stable coronary artery disease:are they so different?Long-term outcomes in a contemporary PCI cohort[J].Int J Cardiol,2013,167(4):1343-1346.
                                    </a>
                                </li>
                                <li id="9">


                                    <a id="bibliography_3" title="Nagata I,Ike A,Nishikawa H,et al.Associations between lipid profiles and MACE in hemodialysis patients with percutaneous coronary intervention:from the FU-Registry[J].J Cardiol,2015,65(2):105-111." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES14061700190417&amp;v=MDY2NDRaZVp0RmlubFVyZklJVm9SYnhzPU5pZk9mYks4SHRmTnFJOUZaZUlQQ0gwK29CTVQ2VDRQUUgvaXJSZEdlcnFRVE1udw==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[3]</b>
                                        Nagata I,Ike A,Nishikawa H,et al.Associations between lipid profiles and MACE in hemodialysis patients with percutaneous coronary intervention:from the FU-Registry[J].J Cardiol,2015,65(2):105-111.
                                    </a>
                                </li>
                                <li id="11">


                                    <a id="bibliography_4" title="Samoš M,Fedor M,Kov&lt;mathml id=&quot;13&quot;&gt;&lt;math xmlns=&quot;http://www.w3.org/1998/Math/MathML&quot;&gt;&lt;mrow&gt;&lt;mi&gt;&#225;&lt;/mi&gt;&lt;mover&gt;&lt;mstyle mathsize=&quot;140%&quot; displaystyle=&quot;true&quot;&gt;&lt;mtext&gt;r&lt;/mtext&gt;&lt;/mstyle&gt;&lt;mo&gt;ˇ&lt;/mo&gt;&lt;/mover&gt;&lt;mtext&gt;F&lt;/mtext&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/mathml&gt;,et al.Ticagrelor:a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis?[J].Blood Coagul Fibrinolysis,2016,27(2):117-120." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWKCC995ADD8651E157FA0130E3DFE18684&amp;v=MjY4NjZmY1pjRExGOWpKM3ZzeGJPMEtEUWs0eWhGbG16OThTMytYcjJaRERMT2NRN0tiQ09OdkZTaVdXcjdKSUZwbWFCdUhZZk9HUWxmQnJMVTA1dEJoeGJ5NnhhRT1OaQ==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[4]</b>
                                        Samoš M,Fedor M,Kov&lt;mathml id=&quot;13&quot;&gt;&lt;math xmlns=&quot;http://www.w3.org/1998/Math/MathML&quot;&gt;&lt;mrow&gt;&lt;mi&gt;&#225;&lt;/mi&gt;&lt;mover&gt;&lt;mstyle mathsize=&quot;140%&quot; displaystyle=&quot;true&quot;&gt;&lt;mtext&gt;r&lt;/mtext&gt;&lt;/mstyle&gt;&lt;mo&gt;ˇ&lt;/mo&gt;&lt;/mover&gt;&lt;mtext&gt;F&lt;/mtext&gt;&lt;/mrow&gt;&lt;/math&gt;&lt;/mathml&gt;,et al.Ticagrelor:a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis?[J].Blood Coagul Fibrinolysis,2016,27(2):117-120.
                                    </a>
                                </li>
                                <li id="14">


                                    <a id="bibliography_5" title="Flechtenmacher N,K&#228;mmerer F,Dittmer R,et al.Clopidogrel Resistance in Neurovascular Stenting:Correlations between Light Transmission Aggregometry,VerifyNow,and the Multiplate[J].AJNR Am J Neuroradiol,2015,36(10):1953-1958." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJRS&amp;filename=SJRS15101500000137&amp;v=MjM4OTNCTVQ2VDRQUUgvaXJSZEdlcnFRVE1ud1plWnRGaW5sVXJmSUlWb1JieHM9TmlmWmZiSzlIOUhOcW85RlpPc1BEWDgrbw==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[5]</b>
                                        Flechtenmacher N,K&#228;mmerer F,Dittmer R,et al.Clopidogrel Resistance in Neurovascular Stenting:Correlations between Light Transmission Aggregometry,VerifyNow,and the Multiplate[J].AJNR Am J Neuroradiol,2015,36(10):1953-1958.
                                    </a>
                                </li>
                                <li id="16">


                                    <a id="bibliography_6" >
                                        <b>[6]</b>
                                    中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高型急性冠状动脉综合征诊断和治疗指南(2016)[J].中华心血管病杂志,2017,45(5):359-376.</a>
                                </li>
                                <li id="18">


                                    <a id="bibliography_7" title="Soh SE,Chong YS,Kwek K,et al.Insights from the Growing Up in Singapore Towards Healthy Outcomes (GUSTO) cohort study[J].Ann Nutr Metab,2014,64(3-4):218-225." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SPQD&amp;filename=SPQD15100800008926&amp;v=MDQxMDRvQk1UNlQ0UFFIL2lyUmRHZXJxUVRNbndaZVp0RmlubFVyZklJVm9SYnhzPU5qM2Fhcks5SDlITXA0OUZaT3NIQlg0Lw==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[7]</b>
                                        Soh SE,Chong YS,Kwek K,et al.Insights from the Growing Up in Singapore Towards Healthy Outcomes (GUSTO) cohort study[J].Ann Nutr Metab,2014,64(3-4):218-225.
                                    </a>
                                </li>
                                <li id="20">


                                    <a id="bibliography_8" title="Celik T,Kaya MG,Akpek M,et al.Does Serum Bilirubin level on admission predict TIMI flow grade and in-hospital MACE in patients with STEMI undergoing primary PCI[J].Angiology,2014,65(3):198-204." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Does serum bilirubin level on admission predict TIMI flow grade and in-hospital MACE in patients with STEMI undergoing primary PCI">
                                        <b>[8]</b>
                                        Celik T,Kaya MG,Akpek M,et al.Does Serum Bilirubin level on admission predict TIMI flow grade and in-hospital MACE in patients with STEMI undergoing primary PCI[J].Angiology,2014,65(3):198-204.
                                    </a>
                                </li>
                                <li id="22">


                                    <a id="bibliography_9" title="Ray S.Clopidogrel resistance:the way forward[J].Indian Heart J,2014,66(5):530-534." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES14110600055242&amp;v=Mjc3ODlNbndaZVp0RmlubFVyZklJVm9SYnhzPU5pZk9mYks4SDlETXFZOUZaTzRLRG5nN29CTVQ2VDRQUUgvaXJSZEdlcnFRVA==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[9]</b>
                                        Ray S.Clopidogrel resistance:the way forward[J].Indian Heart J,2014,66(5):530-534.
                                    </a>
                                </li>
                                <li id="24">


                                    <a id="bibliography_10" title="Zhang L,Yang J,Zhu X,et al.Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis[J].Thromb Res,2015,135(3):449-458." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention-a systematic review and meta-analysis">
                                        <b>[10]</b>
                                        Zhang L,Yang J,Zhu X,et al.Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis[J].Thromb Res,2015,135(3):449-458.
                                    </a>
                                </li>
                                <li id="26">


                                    <a id="bibliography_11" title="Jneid H,Anderson JL,Wright RS,et al.2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction(updating the 2007 guideline and replacing the 2011 focused update):a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].Circulation,2012,126(7):875-910." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK12110200050401&amp;v=MTk2MDNQQ0h3NG9CTVQ2VDRQUUgvaXJSZEdlcnFRVE1ud1plWnRGaW5sVXJmSUlWb1JieHM9TmlmY1piSzZIOURNclk5RlpPNA==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[11]</b>
                                        Jneid H,Anderson JL,Wright RS,et al.2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction(updating the 2007 guideline and replacing the 2011 focused update):a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].Circulation,2012,126(7):875-910.
                                    </a>
                                </li>
                                <li id="28">


                                    <a id="bibliography_12" title="Qureshi Z,Hobson AR.Clopidogrel &quot;resistance&quot;:where are we now?[J].Cardiovasc Ther,2013,31(1):3-11." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWD&amp;filename=SJWD130122009945&amp;v=MDQ0NjRaZVp2RnludFU3N01KVnNkTmlmY2FySzdIdERPclk5RmJlSUxDUk04enhVU21EZDlTSDduM3hFOWZidm5Lcmlm&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[12]</b>
                                        Qureshi Z,Hobson AR.Clopidogrel &quot;resistance&quot;:where are we now?[J].Cardiovasc Ther,2013,31(1):3-11.
                                    </a>
                                </li>
                                <li id="30">


                                    <a id="bibliography_13" title="Park SD,Lee MJ,Baek YS,et al.Randomised trial to compare a protective effect of Clopidogrel Versus TIcagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial)[J].EuroIntervention,2016,12(8):e964-e971." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Randomised trial to compare a protective effect of Clopidogrel Versus TIcagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial)">
                                        <b>[13]</b>
                                        Park SD,Lee MJ,Baek YS,et al.Randomised trial to compare a protective effect of Clopidogrel Versus TIcagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial)[J].EuroIntervention,2016,12(8):e964-e971.
                                    </a>
                                </li>
                                <li id="32">


                                    <a id="bibliography_14" title="Verdoia M,Pergolini P,Rolla R,et al.Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor[J].Platelets,2016,27(6):576-582." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=STJD&amp;filename=STJD698235CBE3CA532BE2D9B9FCD0BA99FC&amp;v=MDA3NjVFdDBPbmFVMzJZMUM4T2RUTXpzQ09OdkZTaVdXcjdKSUZwbWFCdUhZZk9HUWxmQnJMVTA1dEJoeGJ5NnhhRT1Oam5CYXJXeEZ0UFBxdnczRWVoOGZYazZ6V1JtNg==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[14]</b>
                                        Verdoia M,Pergolini P,Rolla R,et al.Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor[J].Platelets,2016,27(6):576-582.
                                    </a>
                                </li>
                                <li id="34">


                                    <a id="bibliography_15" title="Goto S,Huang CH,Park SJ,et al.Ticagrelor vs.clopidogrel in Japanese,Korean and Taiwanese patients with acute coronary syndrome-randomized,double-blind,phase III PHILO study[J].Circ J,2015,79(11):2452-2460." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Ticagrelor vs.clopidogrel in Japanese,Korean and Taiwanese patients with acute coronary syndrome-randomized,double-blind,phase III PHILO study">
                                        <b>[15]</b>
                                        Goto S,Huang CH,Park SJ,et al.Ticagrelor vs.clopidogrel in Japanese,Korean and Taiwanese patients with acute coronary syndrome-randomized,double-blind,phase III PHILO study[J].Circ J,2015,79(11):2452-2460.
                                    </a>
                                </li>
                                <li id="36">


                                    <a id="bibliography_16" title="Clavijo LC,Maya J,Carlson G,et al.Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus[J].Cardiovasc Revasc Med,2015,16(8):450-454." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES70FD39A72703DC63DE93D2DE0970E26D&amp;v=MjQ4NjF3aEt5UlZubnpaK1BIMlcyUkk4ZnJMaFI3enJDT052RlNpV1dyN0pJRnBtYUJ1SFlmT0dRbGZCckxVMDV0Qmh4Ynk2eGFFPU5pZk9mYlM0YUtYUHB2NUNadXdQRA==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[16]</b>
                                        Clavijo LC,Maya J,Carlson G,et al.Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus[J].Cardiovasc Revasc Med,2015,16(8):450-454.
                                    </a>
                                </li>
                                <li id="38">


                                    <a id="bibliography_17" title="Dabek J,Glogowska-Ligus J,Szadorska B.Transcription activity of MMP-2 and MMP-9 metalloproteinase genes and their tissue inhibitor (TIMP-2) in acute coronary syndrome patients[J].J Postgrad Med,2013,59(2):115-120." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK13081300016919&amp;v=MDUzMzZRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmZJSVZvUmJ4cz1OaWZjWmJLN0h0bk5ySTlGWk9vSkJYMHdvQk1UNlQ0UA==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[17]</b>
                                        Dabek J,Glogowska-Ligus J,Szadorska B.Transcription activity of MMP-2 and MMP-9 metalloproteinase genes and their tissue inhibitor (TIMP-2) in acute coronary syndrome patients[J].J Postgrad Med,2013,59(2):115-120.
                                    </a>
                                </li>
                                <li id="40">


                                    <a id="bibliography_18" title="Zhang L,Liu N,Zhang J,et al.Effect of Shexiang baoxin pills on clopidogrel resistance in patients with acute coronary syndrome[J].Pak J Pharm Sci,2016,29(6 Suppl):2303-2306." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Effect of Shexiang Baoxin pills on clopidogrel resistance in patients with acute coronary syndrome">
                                        <b>[18]</b>
                                        Zhang L,Liu N,Zhang J,et al.Effect of Shexiang baoxin pills on clopidogrel resistance in patients with acute coronary syndrome[J].Pak J Pharm Sci,2016,29(6 Suppl):2303-2306.
                                    </a>
                                </li>
                                <li id="42">


                                    <a id="bibliography_19" title="Ogita M,Miyauchi K,Morimoto T,et al.Association between circulating matrix metalloproteinase levels and coronary plaque regression after acute coronary syndrome--subanalysis of the JAPAN-ACS study[J].Atherosclerosis,2013,226(1):275-280." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES15120900222506&amp;v=MDcxNzJRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmZJSVZvUmJ4cz1OaWZPZmJLOUg5UE1wbzlGWnVrTkNYdy9vQk1UNlQ0UA==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[19]</b>
                                        Ogita M,Miyauchi K,Morimoto T,et al.Association between circulating matrix metalloproteinase levels and coronary plaque regression after acute coronary syndrome--subanalysis of the JAPAN-ACS study[J].Atherosclerosis,2013,226(1):275-280.
                                    </a>
                                </li>
                                <li id="44">


                                    <a id="bibliography_20" title="Karadeniz M,Duran M,Akyel A,et al.High Sensitive CRP Level Is Associated With Intermediate and High Syntax Score in Patients With Acute Coronary Syndrome[J].Int Heart J,2015,56(4):377-380." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=High Sensitive CRP Level Is Associated With Intermediate and High Syntax Score in Patients With Acute Coronary Syndrome">
                                        <b>[20]</b>
                                        Karadeniz M,Duran M,Akyel A,et al.High Sensitive CRP Level Is Associated With Intermediate and High Syntax Score in Patients With Acute Coronary Syndrome[J].Int Heart J,2015,56(4):377-380.
                                    </a>
                                </li>
                                <li id="46">


                                    <a id="bibliography_21" title="Abhashi SA,Kryeziu FU,Nazreku FD.Increased carotid intima-media thickness associated with high hsCRP levels is a predictor of unstable coronary artery disease[J].Cardiovasc J Afr,2013,24(7):270-273." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJSN&amp;filename=SJSNC8F3B6AE1C1FDB68A3999AF29C603BB4&amp;v=MTQ2NzhOdkZTaVdXcjdKSUZwbWFCdUhZZk9HUWxmQnJMVTA1dEJoeGJ5NnhhRT1OaWZZWU1Dd2FOSytxZjR3WlpnT2VnaEx5UjVpNlRaMFFRNlVyaHRHZjdLWE44aWJDTw==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[21]</b>
                                        Abhashi SA,Kryeziu FU,Nazreku FD.Increased carotid intima-media thickness associated with high hsCRP levels is a predictor of unstable coronary artery disease[J].Cardiovasc J Afr,2013,24(7):270-273.
                                    </a>
                                </li>
                                <li id="48">


                                    <a id="bibliography_22" title="Wada H,Dohi T,Miyauchi K,et al.Preprocedural High-Sensitivity C-Reactive Protein Predicts Long-Term Outcome of Percutaneous Coronary Intervention[J].Circ J,2016,81(1):90-95." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Preprocedural High-Sensitivity C-Reactive Protein Predicts Long-Term Outcome of Percutaneous Coronary Intervention">
                                        <b>[22]</b>
                                        Wada H,Dohi T,Miyauchi K,et al.Preprocedural High-Sensitivity C-Reactive Protein Predicts Long-Term Outcome of Percutaneous Coronary Intervention[J].Circ J,2016,81(1):90-95.
                                    </a>
                                </li>
                            </ul>
                            <div style='display: none;' class="zqscroller" >
                                <h4 class="">附加材料</h4>
                                <ul></ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            &nbsp;
            <!--此处有一空格符 勿删-->
        </div>

        
    <div class="content">



        <!--tips start-->
                            <div class="tips">
                    <a href="http://navi.cnki.net/KNavi/JournalDetail?pcode=CJFD&amp;pykm=XXGK" target="_blank">心血管康复医学杂志</a>
                2019,28(05),648-652 DOI:10.3969/j.issn.1008-0074.2019.05.22            </div>
        <!--tips end-->
            <div class="top-title">
                <h1 class="title">
                    <span class="vm"><b>替格瑞洛治疗氯吡格雷抵抗性急性冠脉综合征患者的临床效果</b></span>
                                    </h1>

            </div>
                        <h2>
                                <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=au&amp;skey=%E7%8E%8B%E5%8A%A0%E5%B3%B0&amp;code=37595960&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">王加峰</a>
                </h2>
                    <h2>
                    <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=in&amp;skey=%E5%B1%B1%E4%B8%9C%E7%9C%81%E8%8C%8C%E5%B9%B3%E5%8E%BF%E4%BA%BA%E6%B0%91%E5%8C%BB%E9%99%A2%E5%BF%83%E5%86%85%E7%A7%91&amp;code=0894871&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">山东省茌平县人民医院心内科</a>
            </h2>

        
<div class="link">
    <a id="aexport" class="icon icon-output"  onclick="" href="javascript:void(0);"><i></i>导出/参考文献</a>
    
    <span class="shareBoard" onmouseover="$('#sharedet').show();$('#this').addClass('shareBoardCUR')" onmouseout="$('#sharedet').hide();$('#this').removeClass('shareBoardCUR')">
        <a class="icon icon-share" href="#"><i></i>分享<em></em></a>
        <ul class="shareHide" id="sharedet" style="display: none;">
            <li><a title="复制链接" class="copy" onclick="" href="#"><i></i>复制链接</a></li>
            <li><a title="分享到新浪微博" class="xl" onclick="" href="javascript:common.ShareAction('xl');"><i></i>新浪微博</a></li>
            <li>
                <a title="分享到微信" class="wx" onclick="" href="#"><i></i>微信扫一扫</a>
                <div class="qrcode"><img src='' alt='' /></div>
            </li>
        </ul>

    </span>
    
    <a id="RefTrack" title="创建引文跟踪" class="icon icon-track" onclick="" href="javascript:void(0);"> <i></i>创建引文跟踪 </a>
    <a id="ashoucang" title="收藏" class="icon icon-favor" onclick="" href="javascript:void(0);"><i></i>收藏</a>
    <a class="icon icon-print" onclick="window.print();" href="javascript:void(0);"><i></i>打印</a>
    
    <!--版本切换 end-->
</div>
                            <div class="data" id="a_abstract">
                <span class="keys">摘<span style="font-family: 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;</span>要：</span>
                <p><b>目的</b>:研究替格瑞洛治疗氯吡格雷抵抗性急性冠脉综合征(CPGR-ACS)患者的临床效果。<b>方法</b>:于我院行经皮冠状动脉介入治疗(PCI)且术后发生CPGR-ACS的患者138例被随机分为常规治疗组(69例,强化氯吡格雷+拜阿司匹林治疗)与替格瑞洛组(69例,替格瑞洛+拜阿司匹林治疗)。连续治疗90d,观察两组治疗前后血小板抑制率(PIR),血清基质金属蛋白酶2(MMP-2)、hsCRP水平,心率变异性(HRV),主要心血管不良事件(MACE)及出血事件。<b>结果</b>:治疗后,与常规治疗组比较,替格瑞洛组血小板抑制率[(25.76±4.63)%比(43.97±6.43)%]显著提高,血清MMP-2[(44.85±4.51)ng/ml比(36.96±3.72) ng/ml]、hsCRP[(11.64±1.2)mg/L比(7.15±0.72)mg/L]水平显著降低,HRV指标中SDNN[(62.87±6.33)ms比(96.86±9.72)ms]、SDANN[(37.62±3.81)ms比(46.38±4.72)ms]、rMSSD[(25.70±2.61)ms比(38.27±3.93)ms]、PNN50[(3.61±0.37)%比(4.93±0.51)%]、HF[(163.27±16.42)ms<sup>2</sup>比(178.68±18.21) ms<sup>2</sup>]值均显著增加, LF[(283.62±28.90) ms<sup>2</sup>比(197.32±20.18) ms<sup>2</sup>]显著减小(<i>P</i>均=0.001)。替格瑞洛组MACE发生率显著低于常规治疗组(2.90%比15.94%,<i>P</i>=0.009)。两组出血事件比较无显著差异(<i>P</i>=0.229)。<b>结论</b>:替格瑞洛治疗氯吡格雷抵抗性急性冠脉综合征患者,疗效显著,安全可靠。</p>
            </div>
                    <div class="data" id="a_keywords">
                <span class="keys">关键词：</span>
                <p>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E6%80%A5%E6%80%A7%E5%86%A0%E7%8A%B6%E5%8A%A8%E8%84%89%E7%BB%BC%E5%90%88%E5%BE%81&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">急性冠状动脉综合征;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E6%B0%AF%E5%90%A1%E6%A0%BC%E9%9B%B7&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">氯吡格雷;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E6%9B%BF%E6%A0%BC%E7%91%9E%E6%B4%9B&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">替格瑞洛;</a>
                </p>
            </div>
        
        <!--brief start-->
        
            <div class="brief">
                    <p>
                                            </p>
                                    <p><b>收稿日期：</b>2018-02-27</p>

            </div>
                    <h1>Therapeutic effect of ticagrelor on patients with clopidogrel resistant acute coronary syndrome</h1>
                    <h2>
                    <span>WANG Jia-feng</span>
            </h2>
                    <h2>
                    <span>Department of Cardiology, People′s Hospital of Chiping County</span>
            </h2>
                            <div class="data" id="a_abstractEN">
                <span class="keys">Abstract：</span>
                <p><b>Objective</b>:To study therapeutic effect of ticagrelor on patients with clopidogrel resistant acute coronary syndrome(CPGR-ACS).<b>Methods</b>: A total of 138 patients underwent PCI and suffered CPGR-ACS after PCI in our hospital were selected. Patients were randomly and equally divided into routine treatment group(received intensive therapy of clopidogrel + aspirin) and ticagrelor group(received ticagrelor + aspirin), both groups were treated for 90 d. Platelet inhibition rate(PIR), serum levels of matrix metalloproteinase(MMP)-2 andhsCRP, heart rate variability(HRV) before and after treatment, incidence of major adverse cardiovascular events(MACE) and hemorrhage were observed and compared between two groups. <b>Results</b>: After treatment, compared with routine treatment group, there was significant rise in PIR [(25.76±4.63)% vs.(43.97±6.43)%], and significant reductions in serum levels of MMP-2[(44.85±4.51)ng/mlvs.(36.96±3.72) ng/ml]and hsCRP[(11.64±1.2)mg/L vs.(7.15±0.72)mg/L]; significant rise in SDNN[(62.87±6.33)msvs.(96.86±9.72)ms],SDANN[(37.62±3.81)msvs.(46.38±4.72)ms],rMSSD[(25.70±2.61)ms vs.(38.27±3.93)ms],PNN50[(3.61±0.37)%vs.(4.93±0.51)%]and HF[(163.27±16.42)ms<sup>2</sup> vs.(178.68±18.21) ms<sup>2</sup>], and significant reduction in LF [(283.62±28.90) ms<sup>2</sup> vs.(197.32±20.18) ms<sup>2</sup>]in ticagrelor group, <i>P</i>=0.001 all. Incidence rate of MACE in ticagrelor group was significantly lower than that of routine treatment group(2.90% vs. 15.94%, <i>P</i>=0.009). There was no significant difference in incidence rate of hemorrhage events between two groups, <i>P</i>=0.229. <b>Conclusion</b>:Ticagrelor possesses significant therapeutic effect on patients with clopidogrel resistant acute coronary syndrome, and it's safe.</p>
            </div>
                    <div class="data" id="a_keywordsEN">
                <span class="keys">Keyword：</span>
                <p>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Acute%20coronary%20syndrome&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Acute coronary syndrome;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Clopidogrel&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Clopidogrel;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Ticagrelor&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Ticagrelor;</a>
                </p>
            </div>
                    <div class="brief">
                
                    <p>
                                            </p>
                                    <p><b>Received：</b> 2018-02-27</p>
                            </div>


        <!--brief start-->
                        <div class="p1">
                    <p id="50">急性冠脉综合征(ACS)是冠脉粥样硬化斑块破裂,并形成血栓阻塞血管的重症心血管疾病<citation id="82" type="reference"><link href="5" rel="bibliography" /><sup>[<a class="sup">1</a>]</sup></citation>。急诊PCI可快速开通阻塞血管,恢复血供,纠正局部缺血缺氧,改善患者症状<citation id="83" type="reference"><link href="7" rel="bibliography" /><sup>[<a class="sup">2</a>]</sup></citation>。资料显示,PCI治疗ACS尽管具有一定优势,但因未从根本上解决血栓形成的原因,术后常易发生急性血栓等心血管不良事件(MACE)<citation id="84" type="reference"><link href="9" rel="bibliography" /><sup>[<a class="sup">3</a>]</sup></citation>。为避免MACE的发生,临床多以氯吡格雷并阿司匹林双联抗血小板方案进行防治<citation id="85" type="reference"><link href="11" rel="bibliography" /><sup>[<a class="sup">4</a>]</sup></citation>。即便如此,仍有部分患者术后发生MACE,提示该类患者具有氯吡格雷抵抗(CPGR)<citation id="86" type="reference"><link href="14" rel="bibliography" /><sup>[<a class="sup">5</a>]</sup></citation>。为有效避免CPGR,改善患者预后,我院于2015年1月～2017年12月将替格瑞洛应用于氯吡格雷抵抗性急性冠脉综合征(CPGR-ACS)患者的临床治疗,效果满意,报告如下。</p>
                </div>
                <h3 id="51" name="51" class="anchor-tag"><b>1 资料与方法</b></h3>
                <h4 class="anchor-tag" id="52" name="52">1.1 一般资料</h4>
                <div class="p1">
                    <p id="53">选择2015年1月～2017年12月于我院行PCI治疗且术后发生CPGR-ACS的患者138例,男70例(50.72%),女68例(49.28%);年龄50～77(66.53±6.67)岁;体重56.68～69.77(63.59±6.42)kg;冠心病病程3.78～6.87(4.04±0.42)年,左室射血分数(LVEF)51.37%～56.82%,平均(53.76±5.44)%;血小板(PLT,136.83～147.53)10<sup>9</sup>/L,平均(140.82±14.19)10<sup>9</sup>/L;既往病史:高血压84例(60.87%),糖尿病55例(39.86%),高脂血症80例(57.97%);支架数1～3个,平均(1.69±0.18)个。纳入标准:依据《非ST段抬高型急性冠状动脉综合征诊断和治疗指南(2016)》<citation id="87" type="reference"><link href="16" rel="bibliography" /><sup>[<a class="sup">6</a>]</sup></citation>诊断标准诊断为ACS,且与基线血小板聚集率相比较,600mg负荷氯吡格雷4h后降低&lt;10%者;知情同意者;无认知功能障碍者。排除标准:对本研究药物过敏者,凝血功能障碍者,出血倾向者,血液系统疾病者,恶性心律失常者,自身免疫性疾病者,90d内大型手术或严重创伤者,重症肝、肾功能障碍者,高尿酸血症者,恶性肿瘤者。入选CPGR-ACS的138例患者按照随机数字表法均分为替格瑞洛组(69例)和常规治疗组(69例),两组基线资料差异无统计学意义(<i>P</i>均&gt;0.05)。见表1。</p>
                </div>
                <div class="area_img" id="54">
                    <p class="img_tit"><b>表</b>1 <b>两组</b>CPGR-ACS<b>患者基线资料比较</b>(n=69) <a class="downexcel" onclick="DownLoadReportExcel(this)">导出到EXCEL</a></p>
                    <p class="img_tit"></p>
                    <p class="img_note"></p>
                    <table id="54" border="1"><tr><td>组别</td><td>男/女<br />(例)</td><td>年龄<br />(岁)</td><td>体重<br />(kg)</td><td>冠心病病程<br />(年)</td><td>左室射血分数<br />(%)</td><td>血小板<br />(×10<sup>9</sup>/L)</td><td>支架数<br />(个)</td><td>高血压<br /><i>n</i>(%)</td><td>糖尿病<br /><i>n</i>(%)</td><td>高脂血症<br /><i>n</i>(%)</td></tr><tr><td><br />替格瑞洛组</td><td>37/32</td><td>66.49±6.64</td><td>63.55±6.39</td><td>3.97±0.38</td><td>53.28±5.40</td><td>138.91±14.02</td><td>1.66±0.17</td><td>40(57.97)</td><td>26(37.68)</td><td>38(56.52)</td></tr><tr><td><br />常规治疗组</td><td>33/36</td><td>66.73±6.70</td><td>63.62±6.45</td><td>4.08±0.46</td><td>53.92±5.51</td><td>142.85±14.28</td><td>1.73±0.19</td><td>44(63.77)</td><td>29(42.03)</td><td>42(60.87)</td></tr><tr><td><br /><i>χ</i><sup>2</sup>/<i>t</i></td><td>0.4605</td><td>0.2113</td><td>0.0640</td><td>1.5314</td><td>0.6897</td><td>1.6354</td><td>2.2807</td><td>0.4832</td><td>0.2701</td><td>0.4724</td></tr><tr><td><br /><i>P</i></td><td>0.4974</td><td>0.8329</td><td>0.9490</td><td>0.1280</td><td>0.4916</td><td>0.1043</td><td>0.0241</td><td>0.4870</td><td>0.6033</td><td>0.4919</td></tr></table>
                    <form name="form" action="/kxreader/Detail/DownloadReportExcel" method="POST" style="display:inline">
                        <input type="hidden" name="hidTable" value="" />
                        <input type="hidden" name="hidFileName" value="" />
                    </form>
                    <p class="img_note">注:CPGR-ACS:氯吡格雷抵抗性急性冠脉综合征。</p>
                    <p class="img_note"></p>
                </div>
                <h4 class="anchor-tag" id="55" name="55">1.2 方法</h4>
                <div class="p1">
                    <p id="56">常规治疗组:该组患者均行氯吡格雷+拜阿司匹林强化治疗。氯吡格雷150mg/次,1次/d,拜阿司匹林100mg/次,1次/d,连续治疗90d。替格瑞洛组:该组患者均行替格瑞洛+拜阿司匹林治疗。替格瑞洛90mg/次,2次/d,拜阿司匹林100mg/次,1次/d,连续治疗90d。</p>
                </div>
                <h4 class="anchor-tag" id="57" name="57">1.3 观察指标</h4>
                <div class="p1">
                    <p id="58">观察两组治疗前后血小板抑制率;血清基质金属蛋白酶(MMP)-2水平;血清高敏C反应蛋白(hsCRP)水平;24 h窦性心搏RR间期的标准差(SNDD);24h每5min正常RR间期平均值标准差(SDANN);相邻正常RR间期差值的均方根(rMSSD);相邻正常RR间期差值&gt;50ms的心搏数占24h总RR间期的百分比(PNN50);高频(HF)、低频(LF)等心率变异性(HRV)指标;MACE及出血事件。血小板抑制率以血栓弹力图检测;血清MMP-2、hsCRP以酶联免疫吸附法检测;HRV指标以美国PI AECG系统检测。按照GUSTO出血分级<citation id="88" type="reference"><link href="18" rel="bibliography" /><sup>[<a class="sup">7</a>]</sup></citation>评价出血事件:严重出血:颅内出血、由于出血引发血流动力学不稳需进行及时处理的危险性出血;中度出血:未影响血流动力学但需进行输血治疗的出血;轻度出血:皮肤瘀斑、牙龈出血、鼻出血等低于中度出血的少量出血。</p>
                </div>
                <h4 class="anchor-tag" id="59" name="59">1.4 统计学分析</h4>
                <div class="p1">
                    <p id="60">采用SPSS 19.0统计软件分析,计量资料以均数±标准差<mathml id="79"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mo stretchy="false">(</mo><mover accent="true"><mi>x</mi><mo>¯</mo></mover><mo>±</mo><mi>s</mi><mo stretchy="false">)</mo></mrow></math></mathml>表示,比较采用<i>t</i>检验,计数资料以百分率表示,比较采用<i>χ</i><sup>2</sup>检验。<i>P</i>&lt;0.05为差异有统计学意义。</p>
                </div>
                <h3 id="61" name="61" class="anchor-tag"><b>2 结 果</b></h3>
                <h4 class="anchor-tag" id="62" name="62">2.1 两组血小板抑制率及血清MMP-2、hsCRP水平比较</h4>
                <div class="p1">
                    <p id="63">治疗前,两组血小板抑制率及血清MMP-2、hsCRP水平差异无统计学意义(<i>P</i>均&gt;0.05);与治疗前比较,治疗后两组血小板抑制率均显著升高,血清MMP-2、hsCRP水平均显著降低(<i>P</i>均=0.001);治疗后,与常规治疗组比较,替格瑞洛组血小板抑制率显著升高,血清MMP-2、hsCRP水平显著降低(<i>P</i>均=0.001)。见表2。</p>
                </div>
                <div class="area_img" id="64">
                    <p class="img_tit"><b>表</b>2 <b>两组血小板抑制率及血清</b>MMP-2、hsCRP<b>水平比较</b><mathml id="80"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mo stretchy="false">(</mo><mover accent="true"><mi>x</mi><mo>¯</mo></mover><mo>±</mo><mi>s</mi><mo>,</mo><mtext>n</mtext><mo>=</mo><mn>6</mn><mn>9</mn><mo stretchy="false">)</mo></mrow></math></mathml> <a class="downexcel" onclick="DownLoadReportExcel(this)">导出到EXCEL</a></p>
                    <p class="img_tit"></p>
                    <p class="img_note"></p>
                    <table id="64" border="1"><tr><td rowspan="2"><br />组别</td><td colspan="3"><br />血小板抑制率(%)</td><td colspan="3">MMP-2(ng/ml)</td><td colspan="3">hsCRP(mg/L)</td></tr><tr><td>治疗前</td><td>治疗后</td><td><i>t</i>/<i>P</i></td><td>治疗前</td><td>治疗后</td><td><i>t</i>/<i>P</i></td><td>治疗前</td><td>治疗后</td><td><i>t</i>/<i>P</i></td></tr><tr><td>替格瑞洛组</td><td>18.98±<br />1.92</td><td>43.97±<br />6.43<sup>**△△</sup></td><td>30.934/0.001</td><td>57.09±<br />5.73</td><td>36.96±<br />3.72<sup>**△△</sup></td><td>24.476/0.001</td><td>21.08±<br />2.11</td><td>7.15±<br />0.72<sup>**△△</sup></td><td>51.901/0.001</td></tr><tr><td><br />常规治疗组</td><td>18.91±1.89</td><td>25.76±4.63<sup>**</sup></td><td>11.378/0.001</td><td>56.98±5.69</td><td>44.85±4.51<sup>**</sup></td><td>13.878/0.001</td><td>21.02±2.09</td><td>11.64±1.20<sup>**</sup></td><td>32.330/0.001</td></tr><tr><td><br /><i>t</i></td><td>0.216</td><td>19.091</td><td></td><td>0.113</td><td>11.211</td><td></td><td>0.168</td><td>26.651</td><td></td></tr><tr><td><br /><i>P</i></td><td>0.829</td><td>0.001</td><td></td><td>0.910</td><td>0.001</td><td></td><td>0.867</td><td>0.001</td><td></td></tr></table>
                    <form name="form" action="/kxreader/Detail/DownloadReportExcel" method="POST" style="display:inline">
                        <input type="hidden" name="hidTable" value="" />
                        <input type="hidden" name="hidFileName" value="" />
                    </form>
                    <p class="img_note">注:hsCRP:高敏C反应蛋白,MMP-2:基质金属蛋白酶2。与治疗前比较*<i>P</i>&lt;0.05,**<i>P</i>&lt;0.01;与常规治疗组比较△<i>P</i>&lt;0.05,△△<i>P</i>&lt;0.01。下表同。</p>
                    <p class="img_note"></p>
                </div>
                <h4 class="anchor-tag" id="65" name="65">2.2 两组HRV指标比较</h4>
                <div class="p1">
                    <p id="66">治疗前,两组HRV指标差异无统计学意义(<i>P</i>&gt;0.05);与治疗前比较,治疗后两组SNDD、SDANN、rMSSD、PNN50、HF显著增大,LF显著减小(<i>P</i>&lt;0.05或&lt;0.01);治疗后,与常规治疗组比较,替格瑞洛组SNDD、SDANN、rMSSD、PNN50、HF显著增大,LF显著减小(<i>P</i>均=0.001)。见表3。</p>
                </div>
                <div class="area_img" id="67">
                    <p class="img_tit"><b>表</b>3 <b>两组心率变异</b>(HRV)<b>指标比较</b><mathml id="81"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mo stretchy="false">(</mo><mover accent="true"><mi>x</mi><mo>¯</mo></mover><mo>±</mo><mi>s</mi><mo>,</mo><mtext>n</mtext><mo>=</mo><mn>6</mn><mn>9</mn><mo stretchy="false">)</mo></mrow></math></mathml> <a class="downexcel" onclick="DownLoadReportExcel(this)">导出到EXCEL</a></p>
                    <p class="img_tit"></p>
                    <p class="img_note"></p>
                    <table id="67" border="1"><tr><td><br />指标</td><td></td><td>替格瑞洛组</td><td>常规治疗组</td><td><i>t</i></td><td><i>P</i></td></tr><tr><td><br />SNDD(ms)</td><td>治疗前</td><td>46.89±4.71</td><td>46.92±4.74</td><td>0.037</td><td>0.970</td></tr><tr><td><br /></td><td>治疗后</td><td>96.86±9.72<sup>**△△</sup></td><td>62.87±6.33<sup>**</sup></td><td>24.341</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td></td><td>38.430/0.001</td><td>16.754/0.001</td><td></td><td></td></tr><tr><td><br />SDANN(ms)</td><td>治疗前</td><td>28.19±2.94</td><td>28.22±2.96</td><td>0.060</td><td>0.953</td></tr><tr><td><br /></td><td>治疗后</td><td>46.38±4.72<sup>**△△</sup></td><td>37.62±3.81<sup>**</sup></td><td>11.996</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td></td><td>27.172/0.001</td><td>16.184/0.001</td><td></td><td></td></tr><tr><td><br />rMSSD(ms)</td><td>治疗前</td><td>19.13±1.92</td><td>19.17±1.96</td><td>0.121</td><td>0.904</td></tr><tr><td><br /></td><td>治疗后</td><td>38.27±3.93<sup>**△△</sup></td><td>25.70±2.61<sup>**</sup></td><td>22.132</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td></td><td>36.349/0.001</td><td>16.618/0.001</td><td></td><td></td></tr><tr><td><br />PNN50(%)</td><td>治疗前</td><td>2.89±0.30</td><td>2.91±0.32</td><td>0.379</td><td>0.706</td></tr><tr><td><br /></td><td>治疗后</td><td>4.93±0.51<sup>**△△</sup></td><td>3.61±0.37<sup>**</sup></td><td>17.402</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td></td><td>28.639/0.001</td><td>11.886/0.001</td><td></td><td></td></tr><tr><td><br />LF(ms<sup>2</sup>)</td><td>治疗前</td><td>339.86±34.09</td><td>341.77±34.17</td><td>0.329</td><td>0.743</td></tr><tr><td><br /></td><td>治疗后</td><td>197.32±20.18<sup>**△△</sup></td><td>283.62±28.90<sup>**</sup></td><td>20.338</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td></td><td>29.888/0.001</td><td>10.793/0.001</td><td></td><td></td></tr><tr><td><br />HF(ms<sup>2</sup>)</td><td>治疗前</td><td>157.62±16.19</td><td>156.43±16.16</td><td>0.432</td><td>0.666</td></tr><tr><td><br /></td><td>治疗后</td><td>178.68±18.21<sup>**△△</sup></td><td>163.27±16.42<sup>**</sup></td><td>5.221</td><td>0.001</td></tr><tr><td><br /><i>t</i>/<i>P</i></td><td></td><td>7.180/0.001</td><td>2.466/0.015</td><td></td><td></td></tr></table>
                    <form name="form" action="/kxreader/Detail/DownloadReportExcel" method="POST" style="display:inline">
                        <input type="hidden" name="hidTable" value="" />
                        <input type="hidden" name="hidFileName" value="" />
                    </form>
                    <p class="img_note">注:SNDD:24 h窦性心搏RR间期的标准差,SDANN:24h每5min正常RR间期平均值标准差,rMSSD:相邻正常RR间期差值的均方根,PNN50:相邻正常RR间期差值&gt;50ms的心搏数占24h总RR间期的百分比,HF:高频,LF:低频。</p>
                    <p class="img_note"></p>
                </div>
                <h4 class="anchor-tag" id="68" name="68">2.3 两组MACE发生情况比较</h4>
                <div class="p1">
                    <p id="69">替格瑞洛组MACE发生率(2.90%),显著低于常规治疗组(15.94%),<i>P</i>=0.009。见表4。</p>
                </div>
                <div class="area_img" id="70">
                    <p class="img_tit"><b>表</b>4 <b>两组</b>MACE<b>发生情况比较</b>(n=69) <a class="downexcel" onclick="DownLoadReportExcel(this)">导出到EXCEL</a></p>
                    <p class="img_tit"></p>
                    <p class="img_note"></p>
                    <table id="70" border="1"><tr><td><br />组别</td><td>支架内血栓<br /><i>n</i>(%)</td><td>靶血管重建<br /><i>n</i>(%)</td><td>心源性猝死<br /><i>n</i>(%)</td><td>再梗死<br /><i>n</i>(%)</td><td>合计<br /><i>n</i>(%)</td></tr><tr><td><br />替格瑞洛组</td><td>1(1.45)</td><td>1(1.45)</td><td>0(0.00)</td><td>0(0.00)</td><td>2(2.90)<sup>△△</sup></td></tr><tr><td><br />常规治疗组</td><td>3(4.35)</td><td>3(4.35)</td><td>2(2.90)</td><td>3(4.35)</td><td>11(15.94)</td></tr><tr><td><br /><i>t</i></td><td></td><td></td><td></td><td></td><td>6.829</td></tr><tr><td><br /><i>P</i></td><td></td><td></td><td></td><td></td><td>0.009</td></tr></table>
                    <form name="form" action="/kxreader/Detail/DownloadReportExcel" method="POST" style="display:inline">
                        <input type="hidden" name="hidTable" value="" />
                        <input type="hidden" name="hidFileName" value="" />
                    </form>
                    <p class="img_note"></p>
                    <p class="img_note"></p>
                </div>
                <h4 class="anchor-tag" id="71" name="71">2.4 两组出血情况比较</h4>
                <div class="p1">
                    <p id="72">替格瑞洛组轻度出血率(11.59%),与常规治疗组(5.80%)比较差异无统计学意义(<i>P</i>=0.229)。两组均未见中度出血及重度出血患者。见表5。</p>
                </div>
                <div class="area_img" id="73">
                    <p class="img_tit"><b>表</b>5 <b>两组出血情况比较</b>(n=69) <a class="downexcel" onclick="DownLoadReportExcel(this)">导出到EXCEL</a></p>
                    <p class="img_tit"></p>
                    <p class="img_note"></p>
                    <table id="73" border="1"><tr><td><br />组别</td><td>轻度出血<br /><i>n</i>(%)</td><td>中度出血<br /><i>n</i>(%)</td><td>重度出血<br /><i>n</i>(%)</td></tr><tr><td><br />替格瑞洛组</td><td>8(11.59)</td><td>0(0.00)</td><td>0(0.00)</td></tr><tr><td><br />常规治疗组</td><td>4(5.80)</td><td>0(0.00)</td><td>0(0.00)</td></tr><tr><td><br /><i>t</i></td><td>1.450</td><td></td><td></td></tr><tr><td><br /><i>P</i></td><td>0.229</td><td></td><td></td></tr></table>
                    <form name="form" action="/kxreader/Detail/DownloadReportExcel" method="POST" style="display:inline">
                        <input type="hidden" name="hidTable" value="" />
                        <input type="hidden" name="hidFileName" value="" />
                    </form>
                    <p class="img_note"></p>
                    <p class="img_note"></p>
                </div>
                <h3 id="74" name="74" class="anchor-tag"><b>3 讨 论</b></h3>
                <div class="p1">
                    <p id="75">作为创伤性操作,PCI可导致血管内皮损伤,诱发血管炎性反应,激活血小板,引发血小板聚集,释放大量二磷酸腺苷,诱导大量血小板聚集,导致形成支架内血栓、再梗死等MACE<citation id="89" type="reference"><link href="20" rel="bibliography" /><sup>[<a class="sup">8</a>]</sup></citation>。资料显示,作为PCI术后严重并发症,MACE具有较高的致死率,故术后需积极进行抗血小板治疗,以避免MACE的发生<citation id="90" type="reference"><link href="22" rel="bibliography" /><sup>[<a class="sup">9</a>]</sup></citation>。氯吡格雷为噻吩吡啶类P2Y12受体(ADP受体)抑制剂,本体不具有药物活性,在CYP3A4酶作用下,可通过结合血小板膜P2Y12降低血小板活性,达到抵抗血小板聚集的目的<citation id="91" type="reference"><link href="24" rel="bibliography" /><sup>[<a class="sup">10</a>]</sup></citation>。氯吡格雷并阿司匹林为欧洲心脏病学会(ESC)与美国心脏病学会/美国心脏协会(ACC/AHA)指南推荐的抗血小板双联治疗方案<citation id="92" type="reference"><link href="26" rel="bibliography" /><sup>[<a class="sup">11</a>]</sup></citation>。但实践证明,PCI术后部分患者出现CPGR,即对氯吡格雷反应较低或无反应,即便使用氯吡格雷,仍存在较高的MACE发生率<citation id="93" type="reference"><link href="28" rel="bibliography" /><sup>[<a class="sup">12</a>]</sup></citation>。究其原因,主要是由于氯吡格雷需经多次转化才可发挥作用,故其起效缓慢,其作用速度甚至和血小板更新速度相当。</p>
                </div>
                <div class="p1">
                    <p id="76">替格瑞洛为非噻吩吡啶类P2Y12抑制剂,其本体及代谢产物均可抑制P2Y12受体,在体内无需进行转化即可快速发挥抑制血小板聚集的作用,不会因为替格瑞洛代谢酶的差异影响药效<citation id="94" type="reference"><link href="30" rel="bibliography" /><sup>[<a class="sup">13</a>]</sup></citation>;替格瑞洛能够可逆性结合P2Y12受体,不影响P2Y12受体构象,替格瑞洛停止后,血小板即可快速恢复其功能,可有效避免停药后出血事件发生<citation id="95" type="reference"><link href="32" rel="bibliography" /><sup>[<a class="sup">14</a>]</sup></citation>;替格瑞洛服用后吸收迅速,2h内即可达到血药峰值,起效快<citation id="96" type="reference"><link href="34" rel="bibliography" /><sup>[<a class="sup">15</a>]</sup></citation>;替格瑞洛可抑制核苷载体提高细胞外腺苷水平,增强腺苷扩张血管、改善心肌血供、促进药物输送、避免再灌注损伤、抑制血小板及炎性反应等功能<citation id="97" type="reference"><link href="36" rel="bibliography" /><sup>[<a class="sup">16</a>]</sup></citation>。在本研究中,替格瑞洛组血小板抑制率显著高于常规治疗组,HRV指标显著优于常规治疗组,提示替格瑞洛可有效抑制血小板聚集,改善心肌血供,提高心功能。</p>
                </div>
                <div class="p1">
                    <p id="77">MMP-2为蛋白水解酶,可促进细胞外基质的降解<citation id="98" type="reference"><link href="38" rel="bibliography" /><sup>[<a class="sup">17</a>]</sup></citation>。研究证明,MMP-2过度表达于易损斑块,可快速降解弹力纤维及胶原等细胞外基质,干预血管平滑肌细胞的正常生长,促进其凋亡,从而减少斑块支撑,致使斑块破裂并最终导致ACS<citation id="99" type="reference"><link href="40" rel="bibliography" /><sup>[<a class="sup">18</a>]</sup></citation>。研究证明,MMP-2活性增强是斑块稳定性丧失的生化基础。血清MMP-2水平与斑块稳定性直接相关<citation id="100" type="reference"><link href="42" rel="bibliography" /><sup>[<a class="sup">19</a>]</sup></citation>。hsCRP为敏感性较强的炎性介质,可识别并激活影响防卫机制及炎性反应的物质及补体,激活吞噬细胞<citation id="101" type="reference"><link href="44" rel="bibliography" /><sup>[<a class="sup">20</a>]</sup></citation>。研究证明,炎性因子是促进冠脉粥样硬化的重要因素,在冠脉粥样硬化发生发展进程中,hsCRP发挥着重要作用<citation id="102" type="reference"><link href="46" rel="bibliography" /><sup>[<a class="sup">21</a>]</sup></citation>。资料显示,hsCRP和心肌损伤程度直接相关,血清hsCRP水平能准确评估心肌坏死程度及ACS患者预后<citation id="103" type="reference"><link href="48" rel="bibliography" /><sup>[<a class="sup">22</a>]</sup></citation>。在本研究中,治疗后替格瑞洛组血清MMP-2、hsCRP水平显著低于常规治疗组,且MACE发生率低于常规治疗组,说明替格瑞洛可显著降低CPGR-ACS患者血清MMP-2、hsCRP水平,抑制易损斑块形成与脱落,避免MACE的发生。</p>
                </div>
                <div class="p1">
                    <p id="78">总之,替格瑞洛治疗CPGR-ACS可显著抑制血小板聚集,降低血清MMP-2、hsCRP水平,改善心肌血供,提高心功能,避免发生MACE,有利于患者术后康复。</p>
                </div>

        <!--brief end-->
        
        <!--conten left  end-->
        <!--增强附件-->
        

        <!--reference start-->
            <div class="reference anchor-tag" id="a_bibliography">
                    <h3>参考文献</h3>
                                        <p id="5">
                            <a id="bibliography_1" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES14121200000970&amp;v=MTUxMTZCWHM1b0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmZJSVZvUmJ4cz1OaWZPZmJLOEg5UE5yWTlGWk9zUA==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[1]</b>Zakroysky P,Thai WE,Deaňo RC,et al.Steroid exposure,acute coronary syndrome,and inflammatory bowel disease:insights into the inflammatory milieu[J].Am J Med,2015,128(3):303-311.
                            </a>
                        </p>
                        <p id="7">
                            <a id="bibliography_2" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13012300499533&amp;v=MDQ2OTVPZmJLN0h0RE9ySTlGWU9JR0NYODZvQk1UNlQ0UFFIL2lyUmRHZXJxUVRNbndaZVp0RmlubFVyZklJVm9SYnhzPU5pZg==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[2]</b>Alcock RF,Yong AS,Ng AC,et al.Acute coronary syndrome and stable coronary artery disease:are they so different?Long-term outcomes in a contemporary PCI cohort[J].Int J Cardiol,2013,167(4):1343-1346.
                            </a>
                        </p>
                        <p id="9">
                            <a id="bibliography_3" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES14061700190417&amp;v=MzE0NTRkR2VycVFUTW53WmVadEZpbmxVcmZJSVZvUmJ4cz1OaWZPZmJLOEh0Zk5xSTlGWmVJUENIMCtvQk1UNlQ0UFFIL2lyUg==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[3]</b>Nagata I,Ike A,Nishikawa H,et al.Associations between lipid profiles and MACE in hemodialysis patients with percutaneous coronary intervention:from the FU-Registry[J].J Cardiol,2015,65(2):105-111.
                            </a>
                        </p>
                        <p id="11">
                            <a id="bibliography_4" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWKCC995ADD8651E157FA0130E3DFE18684&amp;v=MTEwMDhJRnBtYUJ1SFlmT0dRbGZCckxVMDV0Qmh4Ynk2eGFFPU5pZmNaY0RMRjlqSjN2c3hiTzBLRFFrNHloRmxtejk4UzMrWHIyWkRETE9jUTdLYkNPTnZGU2lXV3I3Sg==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[4]</b>Samoš M,Fedor M,Kov<mathml id="13"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mi>á</mi><mover><mstyle mathsize="140%" displaystyle="true"><mtext>r</mtext></mstyle><mo>ˇ</mo></mover><mtext>F</mtext></mrow></math></mathml>,et al.Ticagrelor:a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis?[J].Blood Coagul Fibrinolysis,2016,27(2):117-120.
                            </a>
                        </p>
                        <p id="14">
                            <a id="bibliography_5" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJRS&amp;filename=SJRS15101500000137&amp;v=MzI0MjRVcmZJSVZvUmJ4cz1OaWZaZmJLOUg5SE5xbzlGWk9zUERYOCtvQk1UNlQ0UFFIL2lyUmRHZXJxUVRNbndaZVp0RmlubA==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[5]</b>Flechtenmacher N,Kämmerer F,Dittmer R,et al.Clopidogrel Resistance in Neurovascular Stenting:Correlations between Light Transmission Aggregometry,VerifyNow,and the Multiplate[J].AJNR Am J Neuroradiol,2015,36(10):1953-1958.
                            </a>
                        </p>
                        <p id="16">
                            <a id="bibliography_6" >
                                    <b>[6]</b>
                                中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高型急性冠状动脉综合征诊断和治疗指南(2016)[J].中华心血管病杂志,2017,45(5):359-376.
                            </a>
                        </p>
                        <p id="18">
                            <a id="bibliography_7" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SPQD&amp;filename=SPQD15100800008926&amp;v=MTMzMDd3WmVadEZpbmxVcmZJSVZvUmJ4cz1OajNhYXJLOUg5SE1wNDlGWk9zSEJYNC9vQk1UNlQ0UFFIL2lyUmRHZXJxUVRNbg==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[7]</b>Soh SE,Chong YS,Kwek K,et al.Insights from the Growing Up in Singapore Towards Healthy Outcomes (GUSTO) cohort study[J].Ann Nutr Metab,2014,64(3-4):218-225.
                            </a>
                        </p>
                        <p id="20">
                            <a id="bibliography_8" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Does serum bilirubin level on admission predict TIMI flow grade and in-hospital MACE in patients with STEMI undergoing primary PCI">

                                <b>[8]</b>Celik T,Kaya MG,Akpek M,et al.Does Serum Bilirubin level on admission predict TIMI flow grade and in-hospital MACE in patients with STEMI undergoing primary PCI[J].Angiology,2014,65(3):198-204.
                            </a>
                        </p>
                        <p id="22">
                            <a id="bibliography_9" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES14110600055242&amp;v=MTE3MjhRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmZJSVZvUmJ4cz1OaWZPZmJLOEg5RE1xWTlGWk80S0RuZzdvQk1UNlQ0UA==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[9]</b>Ray S.Clopidogrel resistance:the way forward[J].Indian Heart J,2014,66(5):530-534.
                            </a>
                        </p>
                        <p id="24">
                            <a id="bibliography_10" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention-a systematic review and meta-analysis">

                                <b>[10]</b>Zhang L,Yang J,Zhu X,et al.Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis[J].Thromb Res,2015,135(3):449-458.
                            </a>
                        </p>
                        <p id="26">
                            <a id="bibliography_11" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK12110200050401&amp;v=MTMwMTE0b0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmZJSVZvUmJ4cz1OaWZjWmJLNkg5RE1yWTlGWk80UENIdw==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[11]</b>Jneid H,Anderson JL,Wright RS,et al.2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction(updating the 2007 guideline and replacing the 2011 focused update):a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].Circulation,2012,126(7):875-910.
                            </a>
                        </p>
                        <p id="28">
                            <a id="bibliography_12" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWD&amp;filename=SJWD130122009945&amp;v=MTk1NzJGeW50VTc3TUpWc2ROaWZjYXJLN0h0RE9yWTlGYmVJTENSTTh6eFVTbURkOVNIN24zeEU5ZmJ2bktyaWZaZVp2&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[12]</b>Qureshi Z,Hobson AR.Clopidogrel "resistance":where are we now?[J].Cardiovasc Ther,2013,31(1):3-11.
                            </a>
                        </p>
                        <p id="30">
                            <a id="bibliography_13" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Randomised trial to compare a protective effect of Clopidogrel Versus TIcagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial)">

                                <b>[13]</b>Park SD,Lee MJ,Baek YS,et al.Randomised trial to compare a protective effect of Clopidogrel Versus TIcagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial)[J].EuroIntervention,2016,12(8):e964-e971.
                            </a>
                        </p>
                        <p id="32">
                            <a id="bibliography_14" target="_blank" href="/kcms/detail/detail.aspx?dbcode=STJD&amp;filename=STJD698235CBE3CA532BE2D9B9FCD0BA99FC&amp;v=MTc2Njhhcld4RnRQUHF2dzNFZWg4ZlhrNnpXUm02RXQwT25hVTMyWTFDOE9kVE16c0NPTnZGU2lXV3I3SklGcG1hQnVIWWZPR1FsZkJyTFUwNXRCaHhieTZ4YUU9TmpuQg==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[14]</b>Verdoia M,Pergolini P,Rolla R,et al.Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor[J].Platelets,2016,27(6):576-582.
                            </a>
                        </p>
                        <p id="34">
                            <a id="bibliography_15" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Ticagrelor vs.clopidogrel in Japanese,Korean and Taiwanese patients with acute coronary syndrome-randomized,double-blind,phase III PHILO study">

                                <b>[15]</b>Goto S,Huang CH,Park SJ,et al.Ticagrelor vs.clopidogrel in Japanese,Korean and Taiwanese patients with acute coronary syndrome-randomized,double-blind,phase III PHILO study[J].Circ J,2015,79(11):2452-2460.
                            </a>
                        </p>
                        <p id="36">
                            <a id="bibliography_16" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES70FD39A72703DC63DE93D2DE0970E26D&amp;v=MDMyMzlQRHdoS3lSVm5uelorUEgyVzJSSThmckxoUjd6ckNPTnZGU2lXV3I3SklGcG1hQnVIWWZPR1FsZkJyTFUwNXRCaHhieTZ4YUU9TmlmT2ZiUzRhS1hQcHY1Q1p1dw==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[16]</b>Clavijo LC,Maya J,Carlson G,et al.Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus[J].Cardiovasc Revasc Med,2015,16(8):450-454.
                            </a>
                        </p>
                        <p id="38">
                            <a id="bibliography_17" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK13081300016919&amp;v=MjM3MzdiSzdIdG5Ockk5RlpPb0pCWDB3b0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmZJSVZvUmJ4cz1OaWZjWg==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[17]</b>Dabek J,Glogowska-Ligus J,Szadorska B.Transcription activity of MMP-2 and MMP-9 metalloproteinase genes and their tissue inhibitor (TIMP-2) in acute coronary syndrome patients[J].J Postgrad Med,2013,59(2):115-120.
                            </a>
                        </p>
                        <p id="40">
                            <a id="bibliography_18" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Effect of Shexiang Baoxin pills on clopidogrel resistance in patients with acute coronary syndrome">

                                <b>[18]</b>Zhang L,Liu N,Zhang J,et al.Effect of Shexiang baoxin pills on clopidogrel resistance in patients with acute coronary syndrome[J].Pak J Pharm Sci,2016,29(6 Suppl):2303-2306.
                            </a>
                        </p>
                        <p id="42">
                            <a id="bibliography_19" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES15120900222506&amp;v=MDE3MzFQUUgvaXJSZEdlcnFRVE1ud1plWnRGaW5sVXJmSUlWb1JieHM9TmlmT2ZiSzlIOVBNcG85Rlp1a05DWHcvb0JNVDZUNA==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[19]</b>Ogita M,Miyauchi K,Morimoto T,et al.Association between circulating matrix metalloproteinase levels and coronary plaque regression after acute coronary syndrome--subanalysis of the JAPAN-ACS study[J].Atherosclerosis,2013,226(1):275-280.
                            </a>
                        </p>
                        <p id="44">
                            <a id="bibliography_20" target="_blank" href="http://scholar.cnki.net/result.aspx?q=High Sensitive CRP Level Is Associated With Intermediate and High Syntax Score in Patients With Acute Coronary Syndrome">

                                <b>[20]</b>Karadeniz M,Duran M,Akyel A,et al.High Sensitive CRP Level Is Associated With Intermediate and High Syntax Score in Patients With Acute Coronary Syndrome[J].Int Heart J,2015,56(4):377-380.
                            </a>
                        </p>
                        <p id="46">
                            <a id="bibliography_21" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJSN&amp;filename=SJSNC8F3B6AE1C1FDB68A3999AF29C603BB4&amp;v=MTk1MzUwUVE2VXJodEdmN0tYTjhpYkNPTnZGU2lXV3I3SklGcG1hQnVIWWZPR1FsZkJyTFUwNXRCaHhieTZ4YUU9TmlmWVlNQ3dhTksrcWY0d1paZ09lZ2hMeVI1aTZUWg==&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[21]</b>Abhashi SA,Kryeziu FU,Nazreku FD.Increased carotid intima-media thickness associated with high hsCRP levels is a predictor of unstable coronary artery disease[J].Cardiovasc J Afr,2013,24(7):270-273.
                            </a>
                        </p>
                        <p id="48">
                            <a id="bibliography_22" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Preprocedural High-Sensitivity C-Reactive Protein Predicts Long-Term Outcome of Percutaneous Coronary Intervention">

                                <b>[22]</b>Wada H,Dohi T,Miyauchi K,et al.Preprocedural High-Sensitivity C-Reactive Protein Predicts Long-Term Outcome of Percutaneous Coronary Intervention[J].Circ J,2016,81(1):90-95.
                            </a>
                        </p>
            </div>
        <!--reference end-->
        <!--footnote start-->
        <!--footnote end-->



    </div>

        <input id="fileid" type="hidden" value="XXGK201905022" />
        <input id="dpi" type="hidden" value="200" />
    </div>

<script>
var _hmt = _hmt || [];
(function() {
  var hm = document.createElement("script");
  hm.src = "https://hm.baidu.com/hm.js?6e967eb120601ea41b9d312166416aa6";
  var s = document.getElementsByTagName("script")[0];
  s.parentNode.insertBefore(hm, s);
})();
</script>


    


<input id="hid_uid" name="hid_uid" type="hidden" value="WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" />
<input id="hid_kLogin_headerUrl" name="hid_kLogin_headerUrl" type="hidden" value="/KLogin/Request/GetKHeader.ashx%3Fcallback%3D%3F" />
<input id="hid_kLogin_footerUrl" name="hid_kLogin_footerUrl" type="hidden" value="/KLogin/Request/GetKFooter.ashx%3Fcallback%3D%3F" />
<div class="btn-link" style="display: none"><a target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=XXGK201905022&amp;v=MzA0NDVSNFQ2ajU0TzN6cXFCdEdGckNVUjdxZlp1Wm1GeW5oVnJyQlBUWE1aYkc0SDlqTXFvOUhab1FLREg4NHY=&amp;uid=WEEvREcwSlJHSldRa1FhcTdnTnhXM3ZDMVRqL09yd3NFclhuTkdPN3RHTT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">知网节</a></div>
<div class="popflow" id="popupTips" style="display: none;">
    <div class="popflowArr"></div>
    <div class="popflowCot">
        <div class="hd"><a href="javascript:void(0);" onclick="$('#popupTips').hide();$('#popupmsg').html('')" class="close">X</a></div>
        <div class="bd">
            <p class="mes" id="popupmsg" name="popupmsg"></p>
          
        </div>
    </div>
</div>
<input type="hidden" id="myexport" value="//kns.cnki.net" />

<input type="hidden" id="KPCAPIPATH" value="//ishufang.cnki.net" />
<input type="hidden" id="CitedTimes" value="" />
<div class="link" id="GLSearch" style="display: none;">
    <i class="icon-trangle"></i>
    <div class="inner">
        <a class="icon" id="copytext">复制</a>
        <a class="icon" target="_blank" onclick="searchCRFD(this)">工具书搜索</a>
    </div>
</div>




<input id="hidVirtualPath" name="hidVirtualPath" type="hidden" value="/kxreader" />
<script src="/kxreader/bundles/detail?v=842_VlRz_g1CMCLi-M0twVw-4EOFG_noWyi_OsMnrAg1"></script>

<script src="/kxreader/Scripts/layer.min.js" type="text/javascript"></script>

<div id="footerBox" class="rootw footer">
</div>
<script>
    if (typeof FlushLogin == 'function') {
        FlushLogin();
    }
    modifyEcpHeader(true);
</script>

<!--图片放大功能 start-->
<script src="/kxreader/bundles/imagebox?v=W4phPu9SNkGcuPeJclikuVE3PpRyIW_gnfjm_19nynI1"></script>

<script type="text/javascript">
    $(function () {
        var j = $.noConflict();
        j(function () {
            j(".zoom-in,.btn-zoomin").imgbox({
                'alignment': 'center',
                'allowMultiple': false,
                'overlayShow': true
            });
        })
    });
</script>
<!--图片放大功能 end-->
<div class="fixedbar">
    <div class="backtop hiddenV" id="backtop">
        <a id="backTopSide" href="javascript:scroll(0,0);" title=""></a>
    </div>
</div>
<script type="text/javascript" src="/kxreader/Scripts/MathJax-2.6-latest/MathJax.js?config=MML_HTMLorMML-full"></script>


    <link href="/kxreader/Content/css/LeftDetail?v=vAscMyvIPP9NePnbGPkqJ0A5tHOvnzl65tGuRDsf9xg1" rel="stylesheet"/>

</body>
</html>

